The global Oligonucleotide Aptamer market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.

Oligonucleotide Aptamer are short, single-stranded nucleic acid molecules (can be RNA or DNA) that have the ability to bind to a specific target with high affinity and specificity. These aptamers are selected and developed through a method called SELEX (Systematic Evolution of Ligand Enrichment), a process that allows the screening of aptamers that can effectively recognize and bind to a variety of biomolecules, including proteins, small molecules, and cells.

From a downstream perspective, Bioanalysis and Detection accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).

Oligonucleotide Aptamer leading manufacturers including Kaneka Corporation(Eurogentec), Danaher(Integrated DNA Technologies), Genescript, Azenta Life Sciences, Thermofischer, Eurofins Genomics, Merck KGaA, TriLink BioTechnologies, SBS Genetech, Bio-Synthesis Inc, etc., dominate supply; the top five capture approximately % of global revenue, with Kaneka Corporation(Eurogentec) leading 2024 sales at US$ million.

Regional Outlook:

North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).

Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).

Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Oligonucleotide Aptamer market, seamlessly integrating production capacity and sales performance across the value chain. It analyzes historical production, revenue, and sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.

Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.

Critical competitive intelligence profiles manufacturers—capacity, sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation

Scope of Oligonucleotide Aptamer Market Report

Report Metric	Details
Report Name	Oligonucleotide Aptamer Market
Segment by Type	RNA Aptamers DNA Aptamers
Segment by Application	Bioanalysis and Detection Targeted Drug Delivery Cancer Treatment Scientific Research Other
Production by Region	North America Europe China Japan
Sales by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Kaneka Corporation(Eurogentec), Danaher(Integrated DNA Technologies), Genescript, Azenta Life Sciences, Thermofischer, Eurofins Genomics, Merck KGaA, TriLink BioTechnologies, SBS Genetech, Bio-Synthesis Inc, Synbio Technologies, Oligo Factory
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the Oligonucleotide Aptamer study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Maps global production capacity, utilization, and market share (2020–2031), identifies efficient hubs, reveals regulatory/trade policy impacts and bottlenecks.
Chapter 4: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 5: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 6: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 7: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 8: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 9: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 10: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 11: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 12: Profiles manufacturers in depth—details product specs, capacity, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 13: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint and technology, cost drivers, plus downstream channels and distributor roles.
Chapter 14: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 7–11) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 13) and customers (Chapter 6) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 4 and 12).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 13 and 14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Oligonucleotide Aptamer Market report?

Ans: The main players in the Oligonucleotide Aptamer Market are Kaneka Corporation(Eurogentec), Danaher(Integrated DNA Technologies), Genescript, Azenta Life Sciences, Thermofischer, Eurofins Genomics, Merck KGaA, TriLink BioTechnologies, SBS Genetech, Bio-Synthesis Inc, Synbio Technologies, Oligo Factory

What are the Application segmentation covered in the Oligonucleotide Aptamer Market report?

Ans: The Applications covered in the Oligonucleotide Aptamer Market report are Bioanalysis and Detection, Targeted Drug Delivery, Cancer Treatment, Scientific Research, Other

What are the Type segmentation covered in the Oligonucleotide Aptamer Market report?

Ans: The Types covered in the Oligonucleotide Aptamer Market report are RNA Aptamers, DNA Aptamers

1 Study Coverage

1.1 Introduction to Oligonucleotide Aptamer: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global Oligonucleotide Aptamer Market Size by Type, 2020 VS 2024 VS 2031

1.2.2 RNA Aptamers

1.2.3 DNA Aptamers

1.3 Market Segmentation by Application

1.3.1 Global Oligonucleotide Aptamer Market Size by Application, 2020 VS 2024 VS 2031

1.3.2 Bioanalysis and Detection

1.3.3 Targeted Drug Delivery

1.3.4 Cancer Treatment

1.3.5 Scientific Research

1.3.6 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global Oligonucleotide Aptamer Revenue Estimates and Forecasts 2020-2031

2.2 Global Oligonucleotide Aptamer Revenue by Region

2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031

2.2.2 Historical and Forecasted Revenue by Region (2020--2031)

2.2.3 Global Revenue Market Share by Region (2020-2031)

2.3 Global Oligonucleotide Aptamer Sales Estimates and Forecasts 2020-2031

2.4 Global Oligonucleotide Aptamer Sales by Region

2.4.1 Sales Comparison: 2020 VS 2024 VS 2031

2.4.2 Historical and Forecasted Sales by Region (2020-2031)

2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends

2.4.4 Global Sales Market Share by Region (2020-2031)

3 Global Production Analysis

3.1 Global Oligonucleotide Aptamer Production Capacity and Utilization Rates (2020–2031)

3.2 Regional Production: Comparative Analysis (2020 VS 2024 VS 2031)

3.3 Regional Production Dynamics

3.3.1 Historic Production by Region (2020-2025)

3.3.2 Forecasted Production by Region (2026-2031)

3.3.3 Production Market Share by Region (2020-2031)

3.3.4 Regulatory and Trade Policy Impact on Production

3.3.5 Production Capacity Enablers and Constraints

3.4 Key Regional Production Hubs

3.4.1 North America

3.4.2 Europe

3.4.3 China

3.4.4 Japan

4 Competition by Manufacturers

4.1 Global Oligonucleotide Aptamer Sales by Manufacturers

4.1.1 Global Sales Volume by Manufacturers (2020-2025)

4.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)

4.2 Global Oligonucleotide Aptamer Manufacturer Revenue Rankings and Tiers

4.2.1 Global Revenue (Value) by Manufacturers (2020-2025)

4.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)

4.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

4.3 Manufacturer Profitability Profiles and Pricing Strategies

4.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)

4.3.2 Manufacturer-Level Price Trends (2020-2025)

4.4 Key Manufacturers Manufacturing Base and Headquarters

4.5 Main Product Type Market Size by Manufacturers

4.5.1 RNA Aptamers Market Size by Manufacturers

4.5.2 DNA Aptamers Market Size by Manufacturers

4.6 Global Oligonucleotide Aptamer Market Concentration and Dynamics

4.6.1 Global Market Concentration (CR5 and HHI)

4.6.2 Entrant/Exit Impact Analysis

4.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

5 Global Product Segmentation Analysis

5.1 Global Oligonucleotide Aptamer Sales Performance by Type

5.1.1 Global Historical and Forecasted Sales by Type (2020-2031)

5.1.2 Global Sales Market Share by Type (2020-2031)

5.2 Global Oligonucleotide Aptamer Revenue Trends by Type

5.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)

5.2.2 Global Revenue Market Share by Type (2020-2031)

5.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)

5.4 Product Technology Differentiation

5.5 Subtype Dynamics: Growth Leaders, Profitability and Risk

5.5.1 High-Growth Niches and Adoption Drivers

5.5.2 Profitability Hotspots and Cost Drivers

5.5.3 Substitution Threats

6 Global Downstream Application Analysis

6.1 Global Oligonucleotide Aptamer Sales by Application

6.1.1 Global Historical and Forecasted Sales by Application (2020-2031)

6.1.2 Global Sales Market Share by Application (2020-2031)

6.1.3 High-Growth Application Identification

6.1.4 Emerging Application Case Studies

6.2 Global Oligonucleotide Aptamer Revenue by Application

6.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)

6.2.2 Revenue Market Share by Application (2020-2031)

6.3 Global Pricing Dynamics by Application (2020-2031)

6.4 Downstream Customer Analysis

6.4.1 Top Customers by Region

6.4.2 Top Customers by Application

7 North America

7.1 North America Sales Volume and Revenue (2020-2031)

7.2 North America Key Manufacturers Sales Revenue in 2024

7.3 North America Oligonucleotide Aptamer Sales and Revenue by Type (2020-2031)

7.4 North America Oligonucleotide Aptamer Sales and Revenue by Application (2020-2031)

7.5 North America Growth Accelerators and Market Barriers

7.6 North America Oligonucleotide Aptamer Market Size by Country

7.6.1 North America Revenue by Country

7.6.2 North America Sales Trends by Country

7.6.3 US

7.6.4 Canada

7.6.5 Mexico

8 Europe

8.1 Europe Sales Volume and Revenue (2020-2031)

8.2 Europe Key Manufacturers Sales Revenue in 2024

8.3 Europe Oligonucleotide Aptamer Sales and Revenue by Type (2020-2031)

8.4 Europe Oligonucleotide Aptamer Sales and Revenue by Application (2020-2031)

8.5 Europe Growth Accelerators and Market Barriers

8.6 Europe Oligonucleotide Aptamer Market Size by Country

8.6.1 Europe Revenue by Country

8.6.2 Europe Sales Trends by Country

8.6.3 Germany

8.6.4 France

8.6.5 U.K.

8.6.6 Italy

8.6.7 Russia

9 Asia-Pacific

9.1 Asia-Pacific Sales Volume and Revenue (2020-2031)

9.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024

9.3 Asia-Pacific Oligonucleotide Aptamer Sales and Revenue by Type (2020-2031)

9.4 Asia-Pacific Oligonucleotide Aptamer Sales and Revenue by Application (2020-2031)

9.5 Asia-Pacific Oligonucleotide Aptamer Market Size by Region

9.5.1 Asia-Pacific Revenue by Region

9.5.2 Asia-Pacific Sales Trends by Region

9.6 Asia-Pacific Growth Accelerators and Market Barriers

9.7 Southeast Asia

9.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)

9.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand

9.8 China

9.9 Japan

9.10 South Korea

9.11 China Taiwan

9.12 India

10 Central and South America

10.1 Central and South America Sales Volume and Revenue (2020-2031)

10.2 Central and South America Key Manufacturers Sales Revenue in 2024

10.3 Central and South America Oligonucleotide Aptamer Sales and Revenue by Type (2020-2031)

10.4 Central and South America Oligonucleotide Aptamer Sales and Revenue by Application (2020-2031)

10.5 Central and South America Investment Opportunities and Key Challenges

10.6 Central and South America Oligonucleotide Aptamer Market Size by Country

10.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)

10.6.2 Brazil

10.6.3 Argentina

11 Middle East and Africa

11.1 Middle East and Africa Sales Volume and Revenue (2020-2031)

11.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024

11.3 Middle East and Africa Oligonucleotide Aptamer Sales and Revenue by Type (2020-2031)

11.4 Middle East and Africa Oligonucleotide Aptamer Sales and Revenue by Application (2020-2031)

11.5 Middle East and Africa Investment Opportunities and Key Challenges

11.6 Middle East and Africa Oligonucleotide Aptamer Market Size by Country

11.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)

11.6.2 GCC Countries

11.6.3 Turkey

11.6.4 Egypt

11.6.5 South Africa

12 Corporate Profile

12.1 Kaneka Corporation(Eurogentec)

12.1.1 Kaneka Corporation(Eurogentec) Corporation Information

12.1.2 Kaneka Corporation(Eurogentec) Business Overview

12.1.3 Kaneka Corporation(Eurogentec) Oligonucleotide Aptamer Product Models, Descriptions and Specifications

12.1.4 Kaneka Corporation(Eurogentec) Oligonucleotide Aptamer Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.1.5 Kaneka Corporation(Eurogentec) Oligonucleotide Aptamer Sales by Product in 2024

12.1.6 Kaneka Corporation(Eurogentec) Oligonucleotide Aptamer Sales by Application in 2024

12.1.7 Kaneka Corporation(Eurogentec) Oligonucleotide Aptamer Sales by Geographic Area in 2024

12.1.8 Kaneka Corporation(Eurogentec) Oligonucleotide Aptamer SWOT Analysis

12.1.9 Kaneka Corporation(Eurogentec) Recent Developments

12.2 Danaher(Integrated DNA Technologies)

12.2.1 Danaher(Integrated DNA Technologies) Corporation Information

12.2.2 Danaher(Integrated DNA Technologies) Business Overview

12.2.3 Danaher(Integrated DNA Technologies) Oligonucleotide Aptamer Product Models, Descriptions and Specifications

12.2.4 Danaher(Integrated DNA Technologies) Oligonucleotide Aptamer Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.2.5 Danaher(Integrated DNA Technologies) Oligonucleotide Aptamer Sales by Product in 2024

12.2.6 Danaher(Integrated DNA Technologies) Oligonucleotide Aptamer Sales by Application in 2024

12.2.7 Danaher(Integrated DNA Technologies) Oligonucleotide Aptamer Sales by Geographic Area in 2024

12.2.8 Danaher(Integrated DNA Technologies) Oligonucleotide Aptamer SWOT Analysis

12.2.9 Danaher(Integrated DNA Technologies) Recent Developments

12.3 Genescript

12.3.1 Genescript Corporation Information

12.3.2 Genescript Business Overview

12.3.3 Genescript Oligonucleotide Aptamer Product Models, Descriptions and Specifications

12.3.4 Genescript Oligonucleotide Aptamer Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.3.5 Genescript Oligonucleotide Aptamer Sales by Product in 2024

12.3.6 Genescript Oligonucleotide Aptamer Sales by Application in 2024

12.3.7 Genescript Oligonucleotide Aptamer Sales by Geographic Area in 2024

12.3.8 Genescript Oligonucleotide Aptamer SWOT Analysis

12.3.9 Genescript Recent Developments

12.4 Azenta Life Sciences

12.4.1 Azenta Life Sciences Corporation Information

12.4.2 Azenta Life Sciences Business Overview

12.4.3 Azenta Life Sciences Oligonucleotide Aptamer Product Models, Descriptions and Specifications

12.4.4 Azenta Life Sciences Oligonucleotide Aptamer Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.4.5 Azenta Life Sciences Oligonucleotide Aptamer Sales by Product in 2024

12.4.6 Azenta Life Sciences Oligonucleotide Aptamer Sales by Application in 2024

12.4.7 Azenta Life Sciences Oligonucleotide Aptamer Sales by Geographic Area in 2024

12.4.8 Azenta Life Sciences Oligonucleotide Aptamer SWOT Analysis

12.4.9 Azenta Life Sciences Recent Developments

12.5 Thermofischer

12.5.1 Thermofischer Corporation Information

12.5.2 Thermofischer Business Overview

12.5.3 Thermofischer Oligonucleotide Aptamer Product Models, Descriptions and Specifications

12.5.4 Thermofischer Oligonucleotide Aptamer Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.5.5 Thermofischer Oligonucleotide Aptamer Sales by Product in 2024

12.5.6 Thermofischer Oligonucleotide Aptamer Sales by Application in 2024

12.5.7 Thermofischer Oligonucleotide Aptamer Sales by Geographic Area in 2024

12.5.8 Thermofischer Oligonucleotide Aptamer SWOT Analysis

12.5.9 Thermofischer Recent Developments

12.6 Eurofins Genomics

12.6.1 Eurofins Genomics Corporation Information

12.6.2 Eurofins Genomics Business Overview

12.6.3 Eurofins Genomics Oligonucleotide Aptamer Product Models, Descriptions and Specifications

12.6.4 Eurofins Genomics Oligonucleotide Aptamer Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.6.5 Eurofins Genomics Recent Developments

12.7 Merck KGaA

12.7.1 Merck KGaA Corporation Information

12.7.2 Merck KGaA Business Overview

12.7.3 Merck KGaA Oligonucleotide Aptamer Product Models, Descriptions and Specifications

12.7.4 Merck KGaA Oligonucleotide Aptamer Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.7.5 Merck KGaA Recent Developments

12.8 TriLink BioTechnologies

12.8.1 TriLink BioTechnologies Corporation Information

12.8.2 TriLink BioTechnologies Business Overview

12.8.3 TriLink BioTechnologies Oligonucleotide Aptamer Product Models, Descriptions and Specifications

12.8.4 TriLink BioTechnologies Oligonucleotide Aptamer Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.8.5 TriLink BioTechnologies Recent Developments

12.9 SBS Genetech

12.9.1 SBS Genetech Corporation Information

12.9.2 SBS Genetech Business Overview

12.9.3 SBS Genetech Oligonucleotide Aptamer Product Models, Descriptions and Specifications

12.9.4 SBS Genetech Oligonucleotide Aptamer Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.9.5 SBS Genetech Recent Developments

12.10 Bio-Synthesis Inc

12.10.1 Bio-Synthesis Inc Corporation Information

12.10.2 Bio-Synthesis Inc Business Overview

12.10.3 Bio-Synthesis Inc Oligonucleotide Aptamer Product Models, Descriptions and Specifications

12.10.4 Bio-Synthesis Inc Oligonucleotide Aptamer Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.10.5 Bio-Synthesis Inc Recent Developments

12.11 Synbio Technologies

12.11.1 Synbio Technologies Corporation Information

12.11.2 Synbio Technologies Business Overview

12.11.3 Synbio Technologies Oligonucleotide Aptamer Product Models, Descriptions and Specifications

12.11.4 Synbio Technologies Oligonucleotide Aptamer Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.11.5 Synbio Technologies Recent Developments

12.12 Oligo Factory

12.12.1 Oligo Factory Corporation Information

12.12.2 Oligo Factory Business Overview

12.12.3 Oligo Factory Oligonucleotide Aptamer Product Models, Descriptions and Specifications

12.12.4 Oligo Factory Oligonucleotide Aptamer Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.12.5 Oligo Factory Recent Developments

13 Value Chain and Supply-Chain Analysis

13.1 Oligonucleotide Aptamer Industry Chain

13.2 Oligonucleotide Aptamer Upstream Materials Analysis

13.2.1 Raw Materials

13.2.2 Key Suppliers Market Share & Risk Assessment

13.3 Oligonucleotide Aptamer Integrated Production Analysis

13.3.1 Manufacturing Footprint Analysis

13.3.2 Production Technology Overview

13.3.3 Regional Cost Drivers

13.4 Oligonucleotide Aptamer Sales Channels and Distribution Networks

13.4.1 Sales Channels

13.4.2 Distributors

14 Oligonucleotide Aptamer Market Dynamics

14.1 Industry Trends and Evolution

14.2 Market Growth Drivers and Emerging Opportunities

14.3 Market Challenges, Risks, and Restraints

15 Key Findings in the Global Oligonucleotide Aptamer Study

16 Appendix

16.1 Research Methodology

16.1.1 Methodology/Research Approach

16.1.1.1 Research Programs/Design

16.1.1.2 Market Size Estimation

16.1.1.3 Market Breakdown and Data Triangulation

16.1.2 Data Source

16.1.2.1 Secondary Sources

16.1.2.2 Primary Sources

16.2 Author Details

FEATURED COMPANIES

Kaneka Corporation (Eurogentec)

TriLink BioTechnologies

Danaher(Integrated DNA Technologies)

List of Tables

Table 1. Global Oligonucleotide Aptamer Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Global Oligonucleotide Aptamer Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 3. Global Oligonucleotide Aptamer Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 4. Global Oligonucleotide Aptamer Revenue by Region (2020-2025) & (US$ Million)

Table 5. Global Oligonucleotide Aptamer Revenue by Region (2026-2031) & (US$ Million)

Table 6. Global Oligonucleotide Aptamer Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (kg)

Table 7. Global Oligonucleotide Aptamer Sales by Region (2020-2025) & (kg)

Table 8. Global Oligonucleotide Aptamer Sales by Region (2026-2031) & (kg)

Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 10. Global Oligonucleotide Aptamer Production Growth Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (kg)

Table 11. Global Oligonucleotide Aptamer Production by Region (2020-2025) & (kg)

Table 12. Global Oligonucleotide Aptamer Production by Region (2026-2031) & (kg)

Table 13. Global Oligonucleotide Aptamer Sales by Manufacturers (2020-2025) & (kg)

Table 14. Global Oligonucleotide Aptamer Sales Share by Manufacturers (2020-2025)

Table 15. Global Oligonucleotide Aptamer Revenue by Manufacturers (2020-2025) & (US$ Million)

Table 16. Global Oligonucleotide Aptamer Revenue Market Share by Manufacturers (2020-2025)

Table 17. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)

Table 18. Global Oligonucleotide Aptamer by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Aptamer as of 2024)

Table 19. Global Oligonucleotide Aptamer Average Gross Margin (%) by Manufacturer (2020 VS 2024)

Table 20. Global Oligonucleotide Aptamer Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/g)

Table 21. Key Manufacturers Oligonucleotide Aptamer Manufacturing Base and Headquarters

Table 22. Global Oligonucleotide Aptamer Market Concentration Ratio (CR5 and HHI)

Table 23. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis

Table 24. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 25. Global Oligonucleotide Aptamer Sales by Type (2020-2025) & (kg)

Table 26. Global Oligonucleotide Aptamer Sales by Type (2026-2031) & (kg)

Table 27. Global Oligonucleotide Aptamer Revenue by Type (2020-2025) & (US$ Million)

Table 28. Global Oligonucleotide Aptamer Revenue by Type (2026-2031) & (US$ Million)

Table 29. Global Oligonucleotide Aptamer ASP by Type (2020-2031) & (US$/g)

Table 30. Technical Specifications by Key Product Type

Table 31. Global Oligonucleotide Aptamer Sales by Application (2020-2025) & (kg)

Table 32. Global Oligonucleotide Aptamer Sales by Application (2026-2031) & (kg)

Table 33. Oligonucleotide Aptamer High-Growth Sectors Demand CAGR (2024-2031)

Table 34. Global Oligonucleotide Aptamer Revenue by Application (2020-2025) & (US$ Million)

Table 35. Global Oligonucleotide Aptamer Revenue by Application (2026-2031) & (US$ Million)

Table 36. Global Oligonucleotide Aptamer ASP by Application (2020-2031) & (US$/g)

Table 37. Top Customers by Region

Table 38. Top Customers by Application

Table 39. North America Oligonucleotide Aptamer Growth Accelerators and Market Barriers

Table 40. North America Oligonucleotide Aptamer Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 41. North America Oligonucleotide Aptamer Sales (kg) by Country (2020 VS 2024 VS 2031)

Table 42. Europe Oligonucleotide Aptamer Growth Accelerators and Market Barriers

Table 43. Europe Oligonucleotide Aptamer Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 44. Europe Oligonucleotide Aptamer Sales (kg) by Country (2020 VS 2024 VS 2031)

Table 45. Asia-Pacific Oligonucleotide Aptamer Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Asia-Pacific Oligonucleotide Aptamer Sales (kg) by Country (2020 VS 2024 VS 2031)

Table 47. Asia-Pacific Oligonucleotide Aptamer Growth Accelerators and Market Barriers

Table 48. Southeast Asia Oligonucleotide Aptamer Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 49. Central and South America Oligonucleotide Aptamer Investment Opportunities and Key Challenges

Table 50. Central and South America Oligonucleotide Aptamer Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 51. Middle East and Africa Oligonucleotide Aptamer Investment Opportunities and Key Challenges

Table 52. Middle East and Africa Oligonucleotide Aptamer Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 53. Kaneka Corporation(Eurogentec) Corporation Information

Table 54. Kaneka Corporation(Eurogentec) Description and Major Businesses

Table 55. Kaneka Corporation(Eurogentec) Product Models, Descriptions and Specifications

Table 56. Kaneka Corporation(Eurogentec) Capacity, Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 57. Kaneka Corporation(Eurogentec) Sales Value Proportion by Product in 2024

Table 58. Kaneka Corporation(Eurogentec) Sales Value Proportion by Application in 2024

Table 59. Kaneka Corporation(Eurogentec) Sales Value Proportion by Geographic Area in 2024

Table 60. Kaneka Corporation(Eurogentec) Oligonucleotide Aptamer SWOT Analysis

Table 61. Kaneka Corporation(Eurogentec) Recent Developments

Table 62. Danaher(Integrated DNA Technologies) Corporation Information

Table 63. Danaher(Integrated DNA Technologies) Description and Major Businesses

Table 64. Danaher(Integrated DNA Technologies) Product Models, Descriptions and Specifications

Table 65. Danaher(Integrated DNA Technologies) Capacity, Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 66. Danaher(Integrated DNA Technologies) Sales Value Proportion by Product in 2024

Table 67. Danaher(Integrated DNA Technologies) Sales Value Proportion by Application in 2024

Table 68. Danaher(Integrated DNA Technologies) Sales Value Proportion by Geographic Area in 2024

Table 69. Danaher(Integrated DNA Technologies) Oligonucleotide Aptamer SWOT Analysis

Table 70. Danaher(Integrated DNA Technologies) Recent Developments

Table 71. Genescript Corporation Information

Table 72. Genescript Description and Major Businesses

Table 73. Genescript Product Models, Descriptions and Specifications

Table 74. Genescript Capacity, Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 75. Genescript Sales Value Proportion by Product in 2024

Table 76. Genescript Sales Value Proportion by Application in 2024

Table 77. Genescript Sales Value Proportion by Geographic Area in 2024

Table 78. Genescript Oligonucleotide Aptamer SWOT Analysis

Table 79. Genescript Recent Developments

Table 80. Azenta Life Sciences Corporation Information

Table 81. Azenta Life Sciences Description and Major Businesses

Table 82. Azenta Life Sciences Product Models, Descriptions and Specifications

Table 83. Azenta Life Sciences Capacity, Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 84. Azenta Life Sciences Sales Value Proportion by Product in 2024

Table 85. Azenta Life Sciences Sales Value Proportion by Application in 2024

Table 86. Azenta Life Sciences Sales Value Proportion by Geographic Area in 2024

Table 87. Azenta Life Sciences Oligonucleotide Aptamer SWOT Analysis

Table 88. Azenta Life Sciences Recent Developments

Table 89. Thermofischer Corporation Information

Table 90. Thermofischer Description and Major Businesses

Table 91. Thermofischer Product Models, Descriptions and Specifications

Table 92. Thermofischer Capacity, Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 93. Thermofischer Sales Value Proportion by Product in 2024

Table 94. Thermofischer Sales Value Proportion by Application in 2024

Table 95. Thermofischer Sales Value Proportion by Geographic Area in 2024

Table 96. Thermofischer Oligonucleotide Aptamer SWOT Analysis

Table 97. Thermofischer Recent Developments

Table 98. Eurofins Genomics Corporation Information

Table 99. Eurofins Genomics Description and Major Businesses

Table 100. Eurofins Genomics Product Models, Descriptions and Specifications

Table 101. Eurofins Genomics Capacity, Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 102. Eurofins Genomics Recent Developments

Table 103. Merck KGaA Corporation Information

Table 104. Merck KGaA Description and Major Businesses

Table 105. Merck KGaA Product Models, Descriptions and Specifications

Table 106. Merck KGaA Capacity, Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 107. Merck KGaA Recent Developments

Table 108. TriLink BioTechnologies Corporation Information

Table 109. TriLink BioTechnologies Description and Major Businesses

Table 110. TriLink BioTechnologies Product Models, Descriptions and Specifications

Table 111. TriLink BioTechnologies Capacity, Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 112. TriLink BioTechnologies Recent Developments

Table 113. SBS Genetech Corporation Information

Table 114. SBS Genetech Description and Major Businesses

Table 115. SBS Genetech Product Models, Descriptions and Specifications

Table 116. SBS Genetech Capacity, Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 117. SBS Genetech Recent Developments

Table 118. Bio-Synthesis Inc Corporation Information

Table 119. Bio-Synthesis Inc Description and Major Businesses

Table 120. Bio-Synthesis Inc Product Models, Descriptions and Specifications

Table 121. Bio-Synthesis Inc Capacity, Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 122. Bio-Synthesis Inc Recent Developments

Table 123. Synbio Technologies Corporation Information

Table 124. Synbio Technologies Description and Major Businesses

Table 125. Synbio Technologies Product Models, Descriptions and Specifications

Table 126. Synbio Technologies Capacity, Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 127. Synbio Technologies Recent Developments

Table 128. Oligo Factory Corporation Information

Table 129. Oligo Factory Description and Major Businesses

Table 130. Oligo Factory Product Models, Descriptions and Specifications

Table 131. Oligo Factory Capacity, Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 132. Oligo Factory Recent Developments

Table 133. Key Raw Materials Distribution

Table 134. Raw Materials Key Suppliers

Table 135. Critical Raw Material Supplier Concentration (2024) & Risk Index

Table 136. Milestones in Production Technology Evolution

Table 137. Distributors List

Table 138. Market Trends and Market Evolution

Table 139. Market Drivers and Opportunities

Table 140. Market Challenges, Risks, and Restraints

Table 141. Research Programs/Design for This Report

Table 142. Key Data Information from Secondary Sources

Table 143. Key Data Information from Primary Sources

List of Figures

Figure 1. Oligonucleotide Aptamer Product Picture

Figure 2. Global Oligonucleotide Aptamer Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. RNA Aptamers Product Picture

Figure 4. DNA Aptamers Product Picture

Figure 5. Global Oligonucleotide Aptamer Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 6. Bioanalysis and Detection

Figure 7. Targeted Drug Delivery

Figure 8. Cancer Treatment

Figure 9. Scientific Research

Figure 10. Other

Figure 11. Oligonucleotide Aptamer Report Years Considered

Figure 12. Global Oligonucleotide Aptamer Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 13. Global Oligonucleotide Aptamer Revenue (2020-2031) & (US$ Million)

Figure 14. Global Oligonucleotide Aptamer Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Figure 15. Global Oligonucleotide Aptamer Revenue Market Share by Region (2020-2031)

Figure 16. Global Oligonucleotide Aptamer Sales (2020-2031) & (kg)

Figure 17. Global Oligonucleotide Aptamer Sales (CAGR) by Region (2020-2031) (kg)

Figure 18. Global Oligonucleotide Aptamer Sales Market Share by Region (2020-2031)

Figure 19. Global Oligonucleotide Aptamer Capacity, Production and Utilization (2020-2031) & (kg)

Figure 20. Global Oligonucleotide Aptamer Production Trend by Region (2020-2031) (kg)

Figure 21. Global Oligonucleotide Aptamer Production Market Share by Region (2020-2031)

Figure 22. Production Capacity Enablers & Constraints

Figure 23. Oligonucleotide Aptamer Production Growth Rate in North America (2020-2031) & (kg)

Figure 24. Oligonucleotide Aptamer Production Growth Rate in Europe (2020-2031) & (kg)

Figure 25. Oligonucleotide Aptamer Production Growth Rate in China (2020-2031) & (kg)

Figure 26. Oligonucleotide Aptamer Production Growth Rate in Japan (2020-2031) & (kg)

Figure 27. Top 5 and Top 10 Manufacturers Oligonucleotide Aptamer Sales Volume Market Share in 2024

Figure 28. Global Oligonucleotide Aptamer Revenue Market Share Ranking (2024)

Figure 29. Tier Distribution by Revenue Contribution (2020 VS 2024)

Figure 30. RNA Aptamers Revenue Market Share by Manufacturer in 2024

Figure 31. DNA Aptamers Revenue Market Share by Manufacturer in 2024

Figure 32. Type Eight Revenue Market Share by Manufacturer in 2024

Figure 33. Type Nine Revenue Market Share by Manufacturer in 2024

Figure 34. Global Oligonucleotide Aptamer Sales Market Share by Type (2020-2031)

Figure 35. Global Oligonucleotide Aptamer Revenue Market Share by Type (2020-2031)

Figure 36. Global Oligonucleotide Aptamer Sales Market Share by Application (2020-2031)

Figure 37. Global Oligonucleotide Aptamer Revenue Market Share by Application (2020-2031)

Figure 38. North America Oligonucleotide Aptamer Sales YoY (2020-2031) & (kg)

Figure 39. North America Oligonucleotide Aptamer Revenue YoY (2020-2031) & (US$ Million)

Figure 40. North America Top 5 Manufacturers Oligonucleotide Aptamer Sales Revenue (US$ Million) in 2024

Figure 41. North America Oligonucleotide Aptamer Sales Volume (kg) by Type (2020- 2031)

Figure 42. North America Oligonucleotide Aptamer Sales Revenue (US$ Million) by Type (2020 - 2031)

Figure 43. North America Oligonucleotide Aptamer Sales Volume (kg) by Application (2020-2031)

Figure 44. North America Oligonucleotide Aptamer Sales Revenue (US$ Million) by Application (2020-2031)

Figure 45. US Oligonucleotide Aptamer Revenue (2020-2031) & (US$ Million)

Figure 46. Canada Oligonucleotide Aptamer Revenue (2020-2031) & (US$ Million)

Figure 47. Mexico Oligonucleotide Aptamer Revenue (2020-2031) & (US$ Million)

Figure 48. Europe Oligonucleotide Aptamer Sales YoY (2020-2031) & (kg)

Figure 49. Europe Oligonucleotide Aptamer Revenue YoY (2020-2031) & (US$ Million)

Figure 50. Europe Top 5 Manufacturers Oligonucleotide Aptamer Sales Revenue (US$ Million) in 2024

Figure 51. Europe Oligonucleotide Aptamer Sales Volume (kg) by Type (2020-2031)

Figure 52. Europe Oligonucleotide Aptamer Sales Revenue (US$ Million) by Type (2020-2031)

Figure 53. Europe Oligonucleotide Aptamer Sales Volume (kg) by Application (2020-2031)

Figure 54. Europe Oligonucleotide Aptamer Sales Revenue (US$ Million) by Application (2020-2031)

Figure 55. Germany Oligonucleotide Aptamer Revenue (2020-2031) & (US$ Million)

Figure 56. France Oligonucleotide Aptamer Revenue (2020-2031) & (US$ Million)

Figure 57. U.K. Oligonucleotide Aptamer Revenue (2020-2031) & (US$ Million)

Figure 58. Italy Oligonucleotide Aptamer Revenue (2020-2031) & (US$ Million)

Figure 59. Russia Oligonucleotide Aptamer Revenue (2020-2031) & (US$ Million)

Figure 60. Asia-Pacific Oligonucleotide Aptamer Sales YoY (2020-2031) & (kg)

Figure 61. Asia-Pacific Oligonucleotide Aptamer Revenue YoY (2020-2031) & (US$ Million)

Figure 62. Asia-Pacific Top 8 Manufacturers Oligonucleotide Aptamer Sales Revenue (US$ Million) in 2024

Figure 63. Asia-Pacific Oligonucleotide Aptamer Sales Volume (kg) by Type (2020- 2031)

Figure 64. Asia-Pacific Oligonucleotide Aptamer Sales Revenue (US$ Million) by Type (2020- 2031)

Figure 65. Asia-Pacific Oligonucleotide Aptamer Sales Volume (kg) by Application (2020-2031)

Figure 66. Asia-Pacific Oligonucleotide Aptamer Sales Revenue (US$ Million) by Application (2020-2031)

Figure 67. Indonesia Oligonucleotide Aptamer Revenue (2020-2031) & (US$ Million)

Figure 68. Japan Oligonucleotide Aptamer Revenue (2020-2031) & (US$ Million)

Figure 69. South Korea Oligonucleotide Aptamer Revenue (2020-2031) & (US$ Million)

Figure 70. China Taiwan Oligonucleotide Aptamer Revenue (2020-2031) & (US$ Million)

Figure 71. India Oligonucleotide Aptamer Revenue (2020-2031) & (US$ Million)

Figure 72. Central and South America Oligonucleotide Aptamer Sales YoY (2020-2031) & (kg)

Figure 73. Central and South America Oligonucleotide Aptamer Revenue YoY (2020-2031) & (US$ Million)

Figure 74. Central and South America Top 5 Manufacturers Oligonucleotide Aptamer Sales Revenue (US$ Million) in 2024

Figure 75. Central and South America Oligonucleotide Aptamer Sales Volume (kg) by Type (2021-2031)

Figure 76. Central and South America Oligonucleotide Aptamer Sales Revenue (US$ Million) by Type (2020-2031)

Figure 77. Central and South America Oligonucleotide Aptamer Sales Volume (kg) by Application (2020-2031)

Figure 78. Central and South America Oligonucleotide Aptamer Sales Revenue (US$ Million) by Application (2020-2031)

Figure 79. Brazil Oligonucleotide Aptamer Revenue (2020-2025) & (US$ Million)

Figure 80. Argentina Oligonucleotide Aptamer Revenue (2020-2025) & (US$ Million)

Figure 81. Middle East, and Africa Oligonucleotide Aptamer Sales YoY (2020-2031) & (kg)

Figure 82. Middle East and Africa Oligonucleotide Aptamer Revenue YoY (2020-2031) & (US$ Million)

Figure 83. Middle East and Africa Top 5 Manufacturers Oligonucleotide Aptamer Sales Revenue (US$ Million) in 2024

Figure 84. Middle East and Africa Oligonucleotide Aptamer Sales Volume (kg) by Type (2021-2031)

Figure 85. South America Oligonucleotide Aptamer Sales Revenue (US$ Million) by Type (2020-2031)

Figure 86. Middle East and Africa Oligonucleotide Aptamer Sales Volume (kg) by Application (2020-2031)

Figure 87. Middle East and Africa Oligonucleotide Aptamer Sales Revenue (US$ Million) by Application (2020-2031)

Figure 88. GCC Countries Oligonucleotide Aptamer Revenue (2020-2025) & (US$ Million)

Figure 89. Turkey Oligonucleotide Aptamer Revenue (2020-2025) & (US$ Million)

Figure 90. Egypt Oligonucleotide Aptamer Revenue (2020-2025) & (US$ Million)

Figure 91. South Africa Oligonucleotide Aptamer Revenue (2020-2025) & (US$ Million)

Figure 92. Oligonucleotide Aptamer Industry Chain Mapping

Figure 93. Regional Oligonucleotide Aptamer Manufacturing Base Distribution (%)

Figure 94. Oligonucleotide Aptamer Production Process

Figure 95. Regional Oligonucleotide Aptamer Production Cost Structure

Figure 96. Channels of Distribution (Direct Vs Distribution)

Figure 97. Bottom-up and Top-down Approaches for This Report

Figure 98. Data Triangulation

Figure 99. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions